San Diego-based specialty pharmaceutical company, Neurelis, and Finnish specialised drug development firm, Biotie Therapies, have entered into an agreement to further develop the former’s NRL-1 (intranasal diazepam) and to provide the latter with the exclusive option to acquire all its outstanding
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp